- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
AlphaRx Inc. , a leading specialty pharmaceutical company with a unique focus on nanotechnology delivery platforms, will update the medical and investor communities on its product pipeline at the 9th Annual Healthcare Conference in New York, November 5-7, at the Plaza Hotel. Dr. David Milroy, the Director of Medical Research at AlphaRx, will provide detailed reports on the complete product pipeline including Clinical trial updates. Dr. Milroy will also present the latest information on Vansolin(TM), which targets nosocomial pneumonia and has a market value estimate of $3.6 billion. Dr. Milroy will present on Wednesday November 7th at 1:00 p.m. (Eastern Time) in the Kennedy II Room.
A live webcast of AlphaRx's presentation can be accessed by logging onto
A replay of the presentation will be archived for 90 days after the conference, at the same site. For more information, please visit http://www.rodmanandrenshaw.com .
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. While these statements are meant to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. While management believes such representation to be true and accurate based on the information available to the company, actual results may differ materially from those described. The company's operations and business prospects are always subject to risks and uncertainties. Important facts that may cause actual results to differ are set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
For more information, please click here
168 Konrad Crescent
Suite 200, Markham
Ontario, Canada L3R 9T9
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins July 26th, 2016
Accurate design of large icosahedral protein nanocages pushes bioengineering boundaries: Scientists used computational methods to build ten large, two-component, co-assembling icosahedral protein complexes the size of small virus coats July 25th, 2016
Nanometrics Announces Upcoming Investor Events July 20th, 2016